The Experts below are selected from a list of 57 Experts worldwide ranked by ideXlab platform
R. Smith - One of the best experts on this subject based on the ideXlab platform.
-
Subcutaneously administered Recombinant human Beta-Interferon in the treatment of chronic hepatitis B virus infection.
Alimentary pharmacology & therapeutics, 1996Co-Authors: R. Guan, K. G. Yeoh, I. Yap, J. Y. Kang, A. Wee, R. SmithAbstract:BACKGROUND Treatment of chronic replicative hepatitis B virus (HBV) infection is aimed at stopping viral replication and preventing the development of chronic liver disease. Beta-Interferon treatment has been less well studied than alpha-Interferon. METHODS The efficacy and tolerability of a 6-month course of subcutaneously administered human Recombinant Beta-Interferon (rINF-Beta ser) was studied and the results of a low-dose regime compared with a high-dose regime. Twenty patients (17 men and three women), aged 24-54 years, with chronic hepatitis B virus infection (all hepatitis B surface antigen-positive with detectable HBV-DNA in their sera for at least 3 months prior to therapy) were randomized into two treatment groups of 10 patients each. The low-dose group received 6 x 10(6) U/dose and the high-dose group received 30 x 10(6) U/dose, both groups receiving their respective doses three times a week initially for 1 month and continuing for a total of 6 months. RESULTS The treatment was well tolerated in both groups. None of the patients required dosage reduction or cessation of treatment because of side-effects. HBV-DNA decreased in all patients during treatment, demonstrating the anti-viral efficacy of rINF-Beta ser, and was undetectable in 20 and 40% of patients receiving low-dose and high-dose regimes, respectively, at the end of 6 months treatment (P = N.S.). One year after completion of treatment, HBV-DNA was undetectable in 50 and 30% of patients in the low-dose and high-dose groups, respectively (P = N.S.). However, only one patient achieved seroconversion with loss of the hepatitis B surface antigen and appearance of an antihepatitis B 'e' antigen at the end of 18 months. CONCLUSION This study shows that subcutaneously administered rINF-Beta ser is well tolerated, but the optimal dose and duration of treatment still needs to be defined by further studies.
Mary Beth Todd - One of the best experts on this subject based on the ideXlab platform.
-
Recombinant Beta-Interferon in the treatment of patients with metastatic renal cell carcinoma
American Journal of Clinical Oncology, 1996Co-Authors: Sridhar Mani, Mary Beth ToddAbstract:We report on the clinical course of 15 patients with metastatic renal cell carcinoma (RCC) who were treated with Recombinant Beta-Interferon as part of a phase I-II study. There were no objective responders among the 15 patients treated with Recombinant Beta-Interferon at an i.v. dose escalating from 90 X 10 6 to 720 X 10 6 U given three times a week until there was documented disease progression or complete response (CR). Overall median survival was 24 months. One patient refused further treatment after 7 weeks. The major side effects of treatment included cardiovascular events (20%), mental status change requiring cessation ofdrug (6.7%), and grade 3 headaches/myalgias (26.7%). There were no life-threatening side effects observed ; however, cardiac events led to the termination of treatment in three patients. Other minor toxicities included fatigue (46.7%), proteinuria (60%), diarrhea (6.7%), nausea and vomiting (13.3%), persistent fever (6.7%), and transient visual disturbance (6.7%). Thus, at our institution, in a cohort of 15 patients with metastatic RCC, Recombinant Beta-Interferon when given i.v. at a dose ≤720 X 10 6 U three times per week, yielded no clinical antitumor activity. A review of the literature on the use of Beta-Interferon for metastatic RCC suggests that there may be some efficacy, but our experience with escalating i.v. doses ≤720 X 10 6 U given three times a week does not support it. Moreover, at these doses, one may find serious cardiovascular events although further studies need to be done in order to clearly define dose-related side effects as well as optimal efficacy-to-toxicity ratio.
-
Recombinant Beta-Interferon in the treatment of patients with metastatic renal cell carcinoma
American journal of clinical oncology, 1996Co-Authors: Sridhar Mani, Mary Beth Todd, Wen Jen PooAbstract:We report on the clinical course of 15 patients with metastatic renal cell carcinoma (RCC) who were treated with Recombinant Beta-Interferon as part of a phase I-II study. There were no objective responders among the 15 patients treated with Recombinant Beta-Interferon at an i.v. dose escalating from 90 X 10(6) U given three times a week until there was documented disease progression or complete response (CR). Overall median survival was 24 months. One patient refused further treatment after 7 weeks. The major side effects of treatment included cardiovascular events (20%), mental status change requiring cessation of drug (6.7%), and grade 3 headaches/myalgias (26.7%). There were no life-threatening side effects observed; however, cardiac events led to the termination of treatment in three patients. Other minor toxicities included fatigue (46.7%), proteinuria (60%), diarrhea (6.7%), nausea and vomiting (13.3%), persistent fever (6.7%) and transient visual disturbance (6.7%). Thus, at our institution, in a cohort of 15 patients with metastatic RCC, Recombinant Beta-Interferon when given i.V. at a dose < or equal to 720 X 10(6) U three times per week, yielded no clinical antitumor activity. A review of the literature on the use of Beta-Interferon for metastatic RCC suggests that there may be some efficacy, but our experience with escalating i.v. doses < or equal to 720 X 10(6) U given three times a week does not support it. Moreover, at these doses, one may find serious cardiovascular events although further studies need to be done in order to clearly define dose-related side effects as well as optimal efficacy-to-toxicity ratio.
Sridhar Mani - One of the best experts on this subject based on the ideXlab platform.
-
Recombinant Beta-Interferon in the treatment of patients with metastatic renal cell carcinoma
American Journal of Clinical Oncology, 1996Co-Authors: Sridhar Mani, Mary Beth ToddAbstract:We report on the clinical course of 15 patients with metastatic renal cell carcinoma (RCC) who were treated with Recombinant Beta-Interferon as part of a phase I-II study. There were no objective responders among the 15 patients treated with Recombinant Beta-Interferon at an i.v. dose escalating from 90 X 10 6 to 720 X 10 6 U given three times a week until there was documented disease progression or complete response (CR). Overall median survival was 24 months. One patient refused further treatment after 7 weeks. The major side effects of treatment included cardiovascular events (20%), mental status change requiring cessation ofdrug (6.7%), and grade 3 headaches/myalgias (26.7%). There were no life-threatening side effects observed ; however, cardiac events led to the termination of treatment in three patients. Other minor toxicities included fatigue (46.7%), proteinuria (60%), diarrhea (6.7%), nausea and vomiting (13.3%), persistent fever (6.7%), and transient visual disturbance (6.7%). Thus, at our institution, in a cohort of 15 patients with metastatic RCC, Recombinant Beta-Interferon when given i.v. at a dose ≤720 X 10 6 U three times per week, yielded no clinical antitumor activity. A review of the literature on the use of Beta-Interferon for metastatic RCC suggests that there may be some efficacy, but our experience with escalating i.v. doses ≤720 X 10 6 U given three times a week does not support it. Moreover, at these doses, one may find serious cardiovascular events although further studies need to be done in order to clearly define dose-related side effects as well as optimal efficacy-to-toxicity ratio.
-
Recombinant Beta-Interferon in the treatment of patients with metastatic renal cell carcinoma
American journal of clinical oncology, 1996Co-Authors: Sridhar Mani, Mary Beth Todd, Wen Jen PooAbstract:We report on the clinical course of 15 patients with metastatic renal cell carcinoma (RCC) who were treated with Recombinant Beta-Interferon as part of a phase I-II study. There were no objective responders among the 15 patients treated with Recombinant Beta-Interferon at an i.v. dose escalating from 90 X 10(6) U given three times a week until there was documented disease progression or complete response (CR). Overall median survival was 24 months. One patient refused further treatment after 7 weeks. The major side effects of treatment included cardiovascular events (20%), mental status change requiring cessation of drug (6.7%), and grade 3 headaches/myalgias (26.7%). There were no life-threatening side effects observed; however, cardiac events led to the termination of treatment in three patients. Other minor toxicities included fatigue (46.7%), proteinuria (60%), diarrhea (6.7%), nausea and vomiting (13.3%), persistent fever (6.7%) and transient visual disturbance (6.7%). Thus, at our institution, in a cohort of 15 patients with metastatic RCC, Recombinant Beta-Interferon when given i.V. at a dose < or equal to 720 X 10(6) U three times per week, yielded no clinical antitumor activity. A review of the literature on the use of Beta-Interferon for metastatic RCC suggests that there may be some efficacy, but our experience with escalating i.v. doses < or equal to 720 X 10(6) U given three times a week does not support it. Moreover, at these doses, one may find serious cardiovascular events although further studies need to be done in order to clearly define dose-related side effects as well as optimal efficacy-to-toxicity ratio.
Jagdish Butany - One of the best experts on this subject based on the ideXlab platform.
-
murine hepatitis virus strain 1 produces a clinically relevant model of severe acute respiratory syndrome in a j mice
Journal of Virology, 2006Co-Authors: Nadine De Albuquerque, Ehtesham Baig, Jianhua Zhang, Andrea Rowe, Marlena V Habal, Mingfeng Liu, Itay Shalev, Gregory P Downey, Reginald M Gorczynski, Jagdish ButanyAbstract:Severe acute respiratory syndrome (SARS) is a life-threatening infectious disease which has been difficult to study and treat because of the lack of a readily available animal model. Intranasal infection of A/J mice with the coronavirus murine hepatitis virus strain 1 (MHV-1) produced pulmonary pathological features of SARS. All MHV-1-infected A/J mice developed progressive interstitial pneumonitis, including dense macrophage infiltrates, giant cells, and hyaline membranes, resulting in death of all animals. In contrast, other mouse strains developed only mild transitory disease. Infected A/J mice had significantly higher cytokine levels, particularly macrophage chemoattractant protein 1 (MCP-1/CCL-2), gamma Interferon, and tumor necrosis factor alpha. Furthermore, FGL2/fibroleukin mRNA transcripts and protein and fibrin deposits were markedly increased in the lungs of infected A/J mice. These animals developed a less robust type I Interferon response to MHV-1 infection than resistant C57BL/6J mice, and treatment with Recombinant Beta Interferon improved survival. This study describes a potentially useful small animal model of human SARS, defines its pathogenesis, and suggests treatment strategies.
R. Guan - One of the best experts on this subject based on the ideXlab platform.
-
Subcutaneously administered Recombinant human Beta-Interferon in the treatment of chronic hepatitis B virus infection.
Alimentary pharmacology & therapeutics, 1996Co-Authors: R. Guan, K. G. Yeoh, I. Yap, J. Y. Kang, A. Wee, R. SmithAbstract:BACKGROUND Treatment of chronic replicative hepatitis B virus (HBV) infection is aimed at stopping viral replication and preventing the development of chronic liver disease. Beta-Interferon treatment has been less well studied than alpha-Interferon. METHODS The efficacy and tolerability of a 6-month course of subcutaneously administered human Recombinant Beta-Interferon (rINF-Beta ser) was studied and the results of a low-dose regime compared with a high-dose regime. Twenty patients (17 men and three women), aged 24-54 years, with chronic hepatitis B virus infection (all hepatitis B surface antigen-positive with detectable HBV-DNA in their sera for at least 3 months prior to therapy) were randomized into two treatment groups of 10 patients each. The low-dose group received 6 x 10(6) U/dose and the high-dose group received 30 x 10(6) U/dose, both groups receiving their respective doses three times a week initially for 1 month and continuing for a total of 6 months. RESULTS The treatment was well tolerated in both groups. None of the patients required dosage reduction or cessation of treatment because of side-effects. HBV-DNA decreased in all patients during treatment, demonstrating the anti-viral efficacy of rINF-Beta ser, and was undetectable in 20 and 40% of patients receiving low-dose and high-dose regimes, respectively, at the end of 6 months treatment (P = N.S.). One year after completion of treatment, HBV-DNA was undetectable in 50 and 30% of patients in the low-dose and high-dose groups, respectively (P = N.S.). However, only one patient achieved seroconversion with loss of the hepatitis B surface antigen and appearance of an antihepatitis B 'e' antigen at the end of 18 months. CONCLUSION This study shows that subcutaneously administered rINF-Beta ser is well tolerated, but the optimal dose and duration of treatment still needs to be defined by further studies.